Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease

References

• Schapira AH, Emre M, Jenner P, et al. Levodopa in the treatment of Parkinson’s disease. Eur J Neurol. 2009;16(9):982–989.
   PubMed Web of Science ®Google Scholar
• Palma PN, Bonifácio MJ, Almeida L, et al. Restoring dopamine levels. In: Simth HJ, Simons C, Sewell RDE, editors. Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies. Boca Raton (FL): CRC Press; 2007. p. 415–445.
   Google Scholar
• Bonifácio MJ, Palma PN, Almeida L, et al. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev. 2007;13(3):352–379.
   PubMedGoogle Scholar
• Gomes P, Soares-Da-Silva P. Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology. 1999;38(9):1371–1380.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stocchi F. COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology. 2004;62(1 Suppl 1):S72–S81.
   PubMed Web of Science ®Google Scholar
• Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174.
   PubMed Web of Science ®Google Scholar
• Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol. 2009;65(5):443–455.
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001 May;16(3):448–458.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.
   PubMed Web of Science ®Google Scholar
• Koller W, Lees A, Doder M, et al. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov Disord. 2001;16(5):858–866.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol. 1997;42(5):747–755.
   PubMed Web of Science ®Google Scholar
• Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105(4):245–255.
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(1 Suppl 1):S39–46.
   PubMed Web of Science ®Google Scholar
• Dingemanse J. Issues important for rational COMT inhibition. Neurology. 2000;55(11Suppl 4):S24–7–32.
   PubMedGoogle Scholar
• Lang AE, Lees A. Management of Parkinson’s disease: an evidence-based review. Mov Disord. 2002;17(S4):S1–6.
   PubMedGoogle Scholar
• Kiss LE, Ferreira HS, Torrão L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396–3411.
   PubMed Web of Science ®Google Scholar
• Guldberg HC, Marsden C. Catechol-O-Methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27(2):136–205.
   Web of Science ®Google Scholar
• Myöhänen TT, Schendzielorz N, Männistö PT. Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J Neurochem. 2010;113(6):1632–1643.
   PubMed Web of Science ®Google Scholar
• Palma PN, Bonifácio M, Loureiro A, et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem. 2012;33(9):970–986.
   PubMed Web of Science ®Google Scholar
• Gonçalves D, Alves G, Fortuna A, et al. A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. Neuropharmacology. 2017;125:146–155.
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Torrão L, Loureiro AI, et al. Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord. 2012;18(S2):S125.
   PubMedGoogle Scholar
• Bonifácio MJ, Torrão L, Loureiro AI, et al. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015;172(7):1739–1752.
   PubMed Web of Science ®Google Scholar
• Almeida L, Rocha JF, Falcão A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-o-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139–151.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Almeida L, Falcão A, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76(5):763–775.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Falcão A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70(9):1059–1071.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Rocha JF, Falcão A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015;22(5):815–825.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Ferreira JJ, Falcão A, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, Catechol-O-Methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2016;5(3):232–240.
   PubMed Web of Science ®Google Scholar
• Falcão A, Rocha JF, Santos A, et al. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. Clin Pharmacol Drug Dev. 2016;5(2):150–161.
   PubMed Web of Science ®Google Scholar
• Müller T, Woitalla D, Fowler B, et al. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm. 2002;109(2):175–179.
   PubMed Web of Science ®Google Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13(6):707–718.
   PubMed Web of Science ®Google Scholar
• Bonifácio MJ, Sutcliffe JS, Torrão L, et al. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology. 2014;77:334–341.
   PubMed Web of Science ®Google Scholar
• Bonifacio M, Sousa F, Loureiro A, et al. Evaluation of potential mechanisms of cellular toxicity by nitrocatechol COMT inhibitors: opicapone, entacapone and tolcapone. XX World Congress on Parkinson’s Disease and Related Disorders; 2013; Switzerland.
   Google Scholar
• Rocha JF, Santos A, Falcão A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014;70(3):279–286.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154–165.
   PubMed Web of Science ®Google Scholar
• Rocha JF, É S, Fauchoux N, et al. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. Br J Clin Pharmacol. 2017;83(3):540–553.
   PubMed Web of Science ®Google Scholar
• Lees A, Ferreira J, Reichmann H, et al. Onset and stabilization of treatment effects in fluctuating Parkinson’s disease patients: exploratory by-week efficacy analysis of pooled phase III studies. Mov Disord. 2016;31(Suppl 2):S642.
   PubMedGoogle Scholar
• Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations. JAMA Neurol. 2017;74(2):197–206.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Lees A, Ferreira J, et al. Opicapone and non-motor symptoms in Parkinson’s disease: results from a double-blind, randomized, placebo-controlled study and open-label extension. Mov Disord. 2015;30(Suppl 1):S173.
   Google Scholar
• Costa R, Oliveira C, Pinto R, et al. One-year open label efficacy and safety of opicapone in Parkinson’s disease BIPARK-II study. Mov Disord. 2014;29(Suppl 1):630.
   Google Scholar
• Lees A, Ferreira J, Lopes N, et al. Efficacy and safety of opicapone in patients over 70 years with Parkinsons disease and motor fluctuations. Mov Disord. 2015;30(Suppl 1):258.
   Google Scholar
• Lopes N, Ferreira J, Lees A, et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease. Mov Disord. 2015;30(Suppl 1):264.
   Google Scholar
• Ferreira J, Lees A, Gama H, et al. Safety and tolerability of opicapone in the treatment of Parkinson’s disease and motor fluctuations: analysis of pooled phase III studies. Mov Disord. 2015;30(Suppl 1):S86.
   Google Scholar
• Pinto R, l’Hostis P, Patat A, et al. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2015;4(6):454–462.
   PubMed Web of Science ®Google Scholar
• MED Collaborative Group P.D Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open label, pragmatic randomised trial. Lancet. 2014;384:1196–1205.
   PubMed Web of Science ®Google Scholar